RxDoctor Payments Data

Nnaemezie Odioemene, MD

Nephrology · Austell, GANPI 1982831616

Payments from drug & device makers

$4,102in general payments, 2019–2025

Across 171 payments — averaging $23.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$660
  • Novartis$523
  • Amgen$407
  • OPKO Pharmaceuticals, LLC$373
  • Aurinia Pharma U.S., Inc.$313
  • Otsuka America Pharmaceutical, Inc.$258
  • plus $2K from 15 others

What the payments were for

  • Food & beverage$3,94296%
  • Education$1604%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,102 in reported general payments places this provider in the 65th percentile of 388 nephrology providers in Georgia.

See all nephrology providers in Georgia

Medicare billing

Part B allowed, 2024
$217,892
Medicare patients
306
Services billed
1,716

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TarpeyoBudesonide11$183,330
XphozahTenapanor Hcl16$69,159
KerendiaFinerenone54$43,195
FarxigaDapagliflozin Propanediol28$27,168
JardianceEmpagliflozin11$11,554
Sevelamer Carbonate74$9,667
Calcium Acetate37$4,213
Nifedipine ErNifedipine125$3,814
Cinacalcet Hcl11$2,420
Hydralazine Hcl87$1,793
Carvedilol154$1,203
Bumetanide36$1,171
Torsemide46$945
Losartan Potassium66$597
Calcitriol37$574

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Calliditas Therapeutics US Inc.Tarpeyo$142$183,33011 claims
BayerKerendia$235$43,19554 claims
AstraZenecaFarxiga$660$27,16828 claims
Boehringer IngelheimJardiance$38$11,55411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 388 nephrology providers in Georgia.

Other nephrology in Austell

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →